Exploring SLAMF5/CD84 in Cancer: Advancing the Frontiers of Tumor Immunology.

IF 3.1 3区 生物学 Q3 CELL BIOLOGY
Safia Obaidur Rab, Ahmed Hussein Zwamel, Ashok Kumar Bishoyi, Suhas Ballal, Abhayveer Singh, Anita Devi, Girish Chandra Sharma, Pushpa Negi Bhakuni, Jasur Rizaev
{"title":"Exploring SLAMF5/CD84 in Cancer: Advancing the Frontiers of Tumor Immunology.","authors":"Safia Obaidur Rab, Ahmed Hussein Zwamel, Ashok Kumar Bishoyi, Suhas Ballal, Abhayveer Singh, Anita Devi, Girish Chandra Sharma, Pushpa Negi Bhakuni, Jasur Rizaev","doi":"10.1002/cbin.70074","DOIUrl":null,"url":null,"abstract":"<p><p>The Signaling Lymphocytic Activation Molecule (SLAM) family receptors play essential roles in regulating immune cell activation, differentiation, and communication. SLAMF5, also known as CD84, has drawn increasing attention in cancer immunology due to its involvement in both tumor progression and immune modulation. This review explores the expression patterns, signaling mechanisms, and functional roles of SLAMF5/CD84 within the tumor microenvironment. SLAMF5/CD84 is expressed on multiple immune cell types and contributes to immune evasion by enhancing regulatory B cell function, promoting myeloid-derived suppressor cell expansion, and upregulating immune checkpoint molecules such as PD-L1. Its expression has been implicated in various hematologic malignancies and solid tumors, including chronic lymphocytic leukemia, multiple myeloma, and triple-negative breast cancer. Emerging therapeutic approaches targeting SLAMF5/CD84-such as monoclonal antibodies and CAR T-cell therapies-offer promising strategies to counteract immunosuppression and improve treatment outcomes. By highlighting recent findings and therapeutic developments, this review underscores the significance of SLAMF5/CD84 as both a prognostic biomarker and a novel target in cancer immunotherapy. Understanding SLAMF5/CD84's multifaceted roles in the tumor immune landscape could support the development of more effective and personalized cancer treatment strategies.</p>","PeriodicalId":9806,"journal":{"name":"Cell Biology International","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Biology International","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/cbin.70074","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The Signaling Lymphocytic Activation Molecule (SLAM) family receptors play essential roles in regulating immune cell activation, differentiation, and communication. SLAMF5, also known as CD84, has drawn increasing attention in cancer immunology due to its involvement in both tumor progression and immune modulation. This review explores the expression patterns, signaling mechanisms, and functional roles of SLAMF5/CD84 within the tumor microenvironment. SLAMF5/CD84 is expressed on multiple immune cell types and contributes to immune evasion by enhancing regulatory B cell function, promoting myeloid-derived suppressor cell expansion, and upregulating immune checkpoint molecules such as PD-L1. Its expression has been implicated in various hematologic malignancies and solid tumors, including chronic lymphocytic leukemia, multiple myeloma, and triple-negative breast cancer. Emerging therapeutic approaches targeting SLAMF5/CD84-such as monoclonal antibodies and CAR T-cell therapies-offer promising strategies to counteract immunosuppression and improve treatment outcomes. By highlighting recent findings and therapeutic developments, this review underscores the significance of SLAMF5/CD84 as both a prognostic biomarker and a novel target in cancer immunotherapy. Understanding SLAMF5/CD84's multifaceted roles in the tumor immune landscape could support the development of more effective and personalized cancer treatment strategies.

探索肿瘤中的SLAMF5/CD84:推进肿瘤免疫学前沿。
信号淋巴细胞活化分子(Signaling Lymphocytic Activation Molecule, SLAM)家族受体在调节免疫细胞活化、分化和通讯中发挥重要作用。SLAMF5也被称为CD84,由于其参与肿瘤进展和免疫调节,在癌症免疫学中引起了越来越多的关注。本文综述了SLAMF5/CD84在肿瘤微环境中的表达模式、信号机制和功能作用。SLAMF5/CD84在多种免疫细胞类型上表达,并通过增强调节性B细胞功能、促进髓源性抑制细胞扩增和上调免疫检查点分子(如PD-L1)参与免疫逃避。它的表达与多种血液恶性肿瘤和实体肿瘤有关,包括慢性淋巴细胞白血病、多发性骨髓瘤和三阴性乳腺癌。新兴的靶向SLAMF5/ cd84的治疗方法,如单克隆抗体和CAR - t细胞疗法,为对抗免疫抑制和改善治疗结果提供了有希望的策略。通过强调最近的发现和治疗进展,本综述强调了SLAMF5/CD84作为预后生物标志物和癌症免疫治疗新靶点的重要性。了解SLAMF5/CD84在肿瘤免疫领域的多方面作用可以支持开发更有效和个性化的癌症治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cell Biology International
Cell Biology International 生物-细胞生物学
CiteScore
7.60
自引率
0.00%
发文量
208
审稿时长
1 months
期刊介绍: Each month, the journal publishes easy-to-assimilate, up-to-the minute reports of experimental findings by researchers using a wide range of the latest techniques. Promoting the aims of cell biologists worldwide, papers reporting on structure and function - especially where they relate to the physiology of the whole cell - are strongly encouraged. Molecular biology is welcome, as long as articles report findings that are seen in the wider context of cell biology. In covering all areas of the cell, the journal is both appealing and accessible to a broad audience. Authors whose papers do not appeal to cell biologists in general because their topic is too specialized (e.g. infectious microbes, protozoology) are recommended to send them to more relevant journals. Papers reporting whole animal studies or work more suited to a medical journal, e.g. histopathological studies or clinical immunology, are unlikely to be accepted, unless they are fully focused on some important cellular aspect. These last remarks extend particularly to papers on cancer. Unless firmly based on some deeper cellular or molecular biological principle, papers that are highly specialized in this field, with limited appeal to cell biologists at large, should be directed towards journals devoted to cancer, there being very many from which to choose.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信